Phase I/II study of melphalan, prednisone and lenalidomide combination for patients with newly diagnosed multiple myeloma who are not candidates for stem cell transplantation

Lignende værker

• Long-term outcome with lenalidomide and dexamethasone therapy for newly diagnosed multiple myeloma
  af: Srivastava, G, et al.
  Udgivet: (2013)
• Lenalidomide, cyclophosphamide and dexamethasone (CRd) for newly diagnosed multiple myeloma: Results from a phase 2 trial
  af: Kumar, Shaji K., et al.
  Udgivet: (2011)
• Melphalan, prednisone, and thalidomide vs melphalan, prednisone, and lenalidomide (ECOG E1A06) in untreated multiple myeloma
  af: Stewart, A. Keith, et al.
  Udgivet: (2015)
• Characteristics of exceptional responders to lenalidomide-based therapy in multiple myeloma
  af: Vu, T, et al.
  Udgivet: (2015)
• The Cost-Effectiveness of Initial Treatment of Multiple Myeloma in the U.S. With Bortezomib Plus Melphalan and Prednisone Versus Thalidomide Plus Melphalan and Prednisone or Lenalidomide Plus Melphalan and Prednisone With Continuous Lenalidomide Maintenance Treatment
  af: Garrison, Louis P., et al.
  Udgivet: (2013)